The Novo Nordisk Foundation in December committed $260 million to create new vaccines for deadly respiratory diseases in partnership with the University of Copenhagen. The new Novo Nordisk Foundation Initiative for Vaccines and Immunity will focus on mucosal vaccines that generate an immune response in the airways themselves, at the site of infection. “[This strategy] is a relatively unexplored area of research with astounding potential,” noted vaccine specialist Peter Lawætz Andersen of the Novo Nordisk Foundation in a press release. Unlike systemic vaccines, after which recipients can still become infected and pass the infection to others, mucosal vaccines have the potential to block infection and prevent airborne transmission.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
About this article
Cite this article
Denmark invests in mucosal vaccines.
Nat Biotechnol 42, 5 (2024). https://doi.org/10.1038/s41587-023-02104-z
Download citation
Published: 17 January 2024
Issue Date: January 2024
DOI: https://doi.org/10.1038/s41587-023-02104-z
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02104-z
